Endocannabinoids were effective against cancer cells with activated BRAF/ERK and/or TrkA signaling, suggesting their potential utility for the treatment of BRAF-positive papillary thyroid carcinoma (PTC) and TrkA-positive medullary thyroid cancer [107]. The gene discussed is NTRK1; the disease is medullary thyroid gland carcinoma.